Drug intelligence / Profile preview

SA-GM-CSF

Development stage: Preclinical
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravesical

Overview

SA-GM-CSF is a novel bifunctional fusion protein designed as an immunotherapy for superficial bladder cancer. It consists of streptavidin (SA) tagged to bioactive granulocyte-macrophage colony-stimulating factor (GM-CSF). The drug works by being intravesically instilled and immobilized on the biotinylated mucosal surface of the bladder wall, leveraging streptavidin's strong binding to biotin. This localized delivery of GM-CSF aims to stimulate an effective anti-tumor immune response, leading to the inhibition of tumor cell growth.

Other names: SA-GM-CSF bifunctional fusion protein

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on SA-GM-CSF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-GM-CSF.

Explore the full profile